A survey on transarterial chemoembolization refractoriness and a real-world treatment pattern for hepatocellular carcinoma in Korea

Clinical and Molecular Hepatology

Jun Yong Park¹  Beom Kyung Kim¹  Seung Up Kim¹  Sang Hoon Ahn¹  Do Young Kim¹  Jae Seung Lee¹  Kwang-Hyub Han¹  Jin Sil Seong² 

[1] Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea;Yonsei Liver Center, Severance Hospital, Seoul, Korea;

关键词: liver neoplasms;    carcinoma, hepatocellular;    embolization, therapeutic;    surveys and questionnaires;   

DOI  :  10.3350/cmh.2018.0065

来源: DOAJ

【 摘 要 】

Background/Aims Transarterial chemoembolization (TACE) is a standard treatment for intermediate-stage hepatocellular carcinoma (HCC), but there is much controversy about TACE refractoriness. The aim of this study was to identify trends in the actual clinical application of TACE and recognition of TACE refractoriness by Korean experts. Methods In total, 17 questionnaires on TACE refractoriness were administered to 161 clinicians via an online survey. Multiple answers were allowed for some questions. Results Most clinicians agreed that there is a need for standardization of TACE application through specific scoring systems (n=124, 77.0%). TACE refractoriness was predominantly expected by participants when recurrences were detected within 1 month (n=70, 43.5%), there were 4 to 6 tumors (n=77, 47.8%), the maximal tumor size was 3–5 cm (n=49, 30.4%), and when there was insufficient tumor necrosis despite TACE being repeated more than three times (n=78, 48.4%). Overall, sorafenib therapy (n=137) and radiotherapy (n=114) were preferred when repeated TACE was considered ineffective. Conclusions Treatment of HCC is often based on the clinical judgment of clinicians because of the heterogeneity among individuals. Experts need to continue discussions on the standardization and sub-classification of HCC treatment guidelines in Korea.

【 授权许可】

Unknown